Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Olema Pharmaceuticals Inc OLMA

Healthcare Biotechnology
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:OLMA)

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

GlobeNewswire 3 days ago

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

PR Newswire 4 days ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2024

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire November 6, 2024

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 4, 2024

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

GlobeNewswire October 23, 2024

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 9, 2024

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 2, 2024

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 4, 2024
View More News ››

Opinion & Analysis (NDAQ:OLMA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:OLMA)

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA): A Promising Biote

http://beyondspx.com/2024/08/02/olema-pharmaceuticals-inc-nasdaqolma-a-promising-biotech-poised-for-significant-growth/
MikeTester - August 3, 2024
View more Bullboard ››

Globex Mining Enterprises Inc.

Globex Mining Enterprises Inc.

Globex Mining Enterprises Inc. is a Canada-based company, which is focused exploration and development property bank which ...
View More »